DUBLIN–(BUSINESS WIRE)–The “Global Pharmaceutical Partnering Terms and Agreements 2016-2020” report has been added to ResearchAndMarkets.com’s offering.

Global Pharmaceutical Partnering Terms and Agreements 2016 to 2020 report provides a detailed understanding and analysis of how and why companies enter Pharmaceutical partnering deals.

The report takes the reader through a comprehensive review Pharmaceutical deal trends, key players, top deal values, as well as deal financials, allowing the understanding of how, why and under what terms, companies are entering Pharmaceutical partnering deals.

The report presents financial deal term values for Pharmaceutical deals, listing by headline value, upfront payments, milestone payments and royalties, enabling readers to analyse and benchmark the financial value of deals.

One of the key highlights of the report is that over 5,500 online deal records of actual Pharmaceutical deals, as disclosed by the deal parties, are included towards the end of the report in a directory format – by company A-Z, stage of development, deal type, therapy focus, and technology type – that is easy to reference. Each deal record in the report links via Weblink to an online version of the deal.

In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners. Whilst many companies will be seeking details of the payment clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.

A comprehensive series of appendices is provided organized by Pharmaceutical partnering company A-Z, stage of development, deal type, and therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each deal on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in Pharmaceutical partnering and dealmaking since 2016.

(Read more…)

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Pharmaceutical technologies and products.

Key benefits

• In-depth understanding of Pharmaceutical deal trends since 2016
• Access to headline, upfront, milestone and royalty data
• Analysis of the structure of Pharmaceutical agreements with real life case studies
• Detailed access to actual Pharmaceutical contracts entered into by leading biopharma companies
• Identify most active Pharmaceutical dealmakers since 2016
• Insight into terms included in a Pharmaceutical partnering agreement, with real world examples
• Understand the key deal terms companies have agreed in previous deals
• Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Available deals are listed by:

• Company A-Z
• Headline value
• Stage of development at signing
• Deal component type
• Specific therapy target
• Technology type

Key Topics Covered:

Executive Summary

Chapter 1 – Introduction

Chapter 2 – Trends in Pharmaceutical dealmaking

2.1. Introduction

2.2. Pharmaceutical partnering over the years

2.3. Most active Pharmaceutical dealmakers

2.4. Pharmaceutical partnering by deal type

2.5. Pharmaceutical partnering by therapy area

2.6. Pharmaceutical partnering by technology type

2.7. Deal terms for Pharmaceutical partnering

2.7.1 Pharmaceutical partnering headline values

2.7.2 Pharmaceutical deal upfront payments

2.7.3 Pharmaceutical deal milestone payments

2.7.4 Pharmaceutical royalty rates

Chapter 3 – Leading Pharmaceutical deals

3.1. Introduction

3.2. Top Pharmaceutical deals by value

Chapter 4 – Most active Pharmaceutical dealmakers

4.1. Introduction

4.2. Most active Pharmaceutical dealmakers

4.3. Most active Pharmaceutical partnering company profiles

Chapter 5 – Pharmaceutical contracts dealmaking directory

5.1. Introduction

5.2. Pharmaceutical contracts dealmaking directory

Chapter 6 – Pharmaceutical dealmaking by technology type

Chapter 7 – Partnering resource center

7.1. Online partnering

7.2. Partnering events

7.3. Further reading on dealmaking

Appendices

Appendix 1 – Pharmaceutical deals by company A-Z

Appendix 2 – Pharmaceutical deals by stage of development

Appendix 3 – Pharmaceutical deals by deal type

Appendix 4 – Pharmaceutical deals by therapy area

Appendix 5 – Deal type definitions

For more information about this report visit https://www.researchandmarkets.com/r/ka6n0a

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]
For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

DUBLIN–(BUSINESS WIRE)–The “Global Pharmaceutical Partnering Terms and Agreements 2016-2020” report has been added to ResearchAndMarkets.com’s offering.

Global Pharmaceutical Partnering Terms and Agreements 2016 to 2020 report provides a detailed understanding and analysis of how and why companies enter Pharmaceutical partnering deals.

The report takes the reader through a comprehensive review Pharmaceutical deal trends, key players, top deal values, as well as deal financials, allowing the understanding of how, why and under what terms, companies are entering Pharmaceutical partnering deals.

The report presents financial deal term values for Pharmaceutical deals, listing by headline value, upfront payments, milestone payments and royalties, enabling readers to analyse and benchmark the financial value of deals.

One of the key highlights of the report is that over 5,500 online deal records of actual Pharmaceutical deals, as disclosed by the deal parties, are included towards the end of the report in a directory format – by company A-Z, stage of development, deal type, therapy focus, and technology type – that is easy to reference. Each deal record in the report links via Weblink to an online version of the deal.

In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners. Whilst many companies will be seeking details of the payment clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.

A comprehensive series of appendices is provided organized by Pharmaceutical partnering company A-Z, stage of development, deal type, and therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each deal on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in Pharmaceutical partnering and dealmaking since 2016.

(Read more…)

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Pharmaceutical technologies and products.

Key benefits

• In-depth understanding of Pharmaceutical deal trends since 2016
• Access to headline, upfront, milestone and royalty data
• Analysis of the structure of Pharmaceutical agreements with real life case studies
• Detailed access to actual Pharmaceutical contracts entered into by leading biopharma companies
• Identify most active Pharmaceutical dealmakers since 2016
• Insight into terms included in a Pharmaceutical partnering agreement, with real world examples
• Understand the key deal terms companies have agreed in previous deals
• Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Available deals are listed by:

• Company A-Z
• Headline value
• Stage of development at signing
• Deal component type
• Specific therapy target
• Technology type

Key Topics Covered:

Executive Summary

Chapter 1 – Introduction

Chapter 2 – Trends in Pharmaceutical dealmaking

2.1. Introduction

2.2. Pharmaceutical partnering over the years

2.3. Most active Pharmaceutical dealmakers

2.4. Pharmaceutical partnering by deal type

2.5. Pharmaceutical partnering by therapy area

2.6. Pharmaceutical partnering by technology type

2.7. Deal terms for Pharmaceutical partnering

2.7.1 Pharmaceutical partnering headline values

2.7.2 Pharmaceutical deal upfront payments

2.7.3 Pharmaceutical deal milestone payments

2.7.4 Pharmaceutical royalty rates

Chapter 3 – Leading Pharmaceutical deals

3.1. Introduction

3.2. Top Pharmaceutical deals by value

Chapter 4 – Most active Pharmaceutical dealmakers

4.1. Introduction

4.2. Most active Pharmaceutical dealmakers

4.3. Most active Pharmaceutical partnering company profiles

Chapter 5 – Pharmaceutical contracts dealmaking directory

5.1. Introduction

5.2. Pharmaceutical contracts dealmaking directory

Chapter 6 – Pharmaceutical dealmaking by technology type

Chapter 7 – Partnering resource center

7.1. Online partnering

7.2. Partnering events

7.3. Further reading on dealmaking

Appendices

Appendix 1 – Pharmaceutical deals by company A-Z

Appendix 2 – Pharmaceutical deals by stage of development

Appendix 3 – Pharmaceutical deals by deal type

Appendix 4 – Pharmaceutical deals by therapy area

Appendix 5 – Deal type definitions

For more information about this report visit https://www.researchandmarkets.com/r/ka6n0a

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]
For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

DUBLIN–(BUSINESS WIRE)–The “Global Pharmaceutical Partnering Terms and Agreements 2016-2020” report has been added to ResearchAndMarkets.com’s offering.

Global Pharmaceutical Partnering Terms and Agreements 2016 to 2020 report provides a detailed understanding and analysis of how and why companies enter Pharmaceutical partnering deals.

The report takes the reader through a comprehensive review Pharmaceutical deal trends, key players, top deal values, as well as deal financials, allowing the understanding of how, why and under what terms, companies are entering Pharmaceutical partnering deals.

The report presents financial deal term values for Pharmaceutical deals, listing by headline value, upfront payments, milestone payments and royalties, enabling readers to analyse and benchmark the financial value of deals.

One of the key highlights of the report is that over 5,500 online deal records of actual Pharmaceutical deals, as disclosed by the deal parties, are included towards the end of the report in a directory format – by company A-Z, stage of development, deal type, therapy focus, and technology type – that is easy to reference. Each deal record in the report links via Weblink to an online version of the deal.

In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners. Whilst many companies will be seeking details of the payment clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.

A comprehensive series of appendices is provided organized by Pharmaceutical partnering company A-Z, stage of development, deal type, and therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each deal on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in Pharmaceutical partnering and dealmaking since 2016.

(Read more…)

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Pharmaceutical technologies and products.

Key benefits

• In-depth understanding of Pharmaceutical deal trends since 2016
• Access to headline, upfront, milestone and royalty data
• Analysis of the structure of Pharmaceutical agreements with real life case studies
• Detailed access to actual Pharmaceutical contracts entered into by leading biopharma companies
• Identify most active Pharmaceutical dealmakers since 2016
• Insight into terms included in a Pharmaceutical partnering agreement, with real world examples
• Understand the key deal terms companies have agreed in previous deals
• Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Available deals are listed by:

• Company A-Z
• Headline value
• Stage of development at signing
• Deal component type
• Specific therapy target
• Technology type

Key Topics Covered:

Executive Summary

Chapter 1 – Introduction

Chapter 2 – Trends in Pharmaceutical dealmaking

2.1. Introduction

2.2. Pharmaceutical partnering over the years

2.3. Most active Pharmaceutical dealmakers

2.4. Pharmaceutical partnering by deal type

2.5. Pharmaceutical partnering by therapy area

2.6. Pharmaceutical partnering by technology type

2.7. Deal terms for Pharmaceutical partnering

2.7.1 Pharmaceutical partnering headline values

2.7.2 Pharmaceutical deal upfront payments

2.7.3 Pharmaceutical deal milestone payments

2.7.4 Pharmaceutical royalty rates

Chapter 3 – Leading Pharmaceutical deals

3.1. Introduction

3.2. Top Pharmaceutical deals by value

Chapter 4 – Most active Pharmaceutical dealmakers

4.1. Introduction

4.2. Most active Pharmaceutical dealmakers

4.3. Most active Pharmaceutical partnering company profiles

Chapter 5 – Pharmaceutical contracts dealmaking directory

5.1. Introduction

5.2. Pharmaceutical contracts dealmaking directory

Chapter 6 – Pharmaceutical dealmaking by technology type

Chapter 7 – Partnering resource center

7.1. Online partnering

7.2. Partnering events

7.3. Further reading on dealmaking

Appendices

Appendix 1 – Pharmaceutical deals by company A-Z

Appendix 2 – Pharmaceutical deals by stage of development

Appendix 3 – Pharmaceutical deals by deal type

Appendix 4 – Pharmaceutical deals by therapy area

Appendix 5 – Deal type definitions

For more information about this report visit https://www.researchandmarkets.com/r/ka6n0a

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]
For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900